![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Physiomics Plc | LSE:PYC | London | Ordinary Share | GB00BDR6W943 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.05 | 7.41% | 0.725 | 0.70 | 0.75 | 0.725 | 0.675 | 0.675 | 868,645 | 15:45:07 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 597k | -477k | -0.0035 | -2.06 | 914.44k |
TIDMPYC
RNS Number : 0202H
Physiomics PLC
25 July 2023
25 July 2023
Physiomics plc
("PYC" or the "Company")
Director Dealing
The Company announces that Dr Jim Millen, Chief Executive Officer of Physiomics, has transferred, for no consideration, 500,000 ordinary shares of 0.4p each in the Company held in certificated form ("Ordinary Shares") to his nominee account with Interactive Investor Services Limited. The Ordinary Shares remain beneficially owned by Dr Millen.
Accordingly, Dr Millen's total holding in the Company will remain unchanged at 1,884,393 Ordinary Shares, representing approximately 1.39 per cent. of the Company's issued share capital.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO +44 (0)1865 784 980
Hybridan LLP (Broker) +44 (0) 203 764 2341
Claire Louise Noyce
Strand Hanson Ltd (NOMAD) +44 (0)20 7409 3494
James Dance
James Bellman
The Company's LEI is 213800A71DSZ6ABMTQ91
PDMR Notification Forms
1. Details of the person discharging managerial responsibilities / person closely associated a) Name James Millen -------------------------------- ---------------------------------------- 2. Reason for the Notification -------------------------------------------------------------------------- a) Position/status Executive Chairman and CEO -------------------------------- ---------------------------------------- b) Initial notification/amendment Initial notification -------------------------------- ---------------------------------------- 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor -------------------------------------------------------------------------- a) Name Physiomics plc -------------------------------- ---------------------------------------- b) LEI 213800A71DSZ6ABMTQ91 -------------------------------- ---------------------------------------- 4. Details of the transaction(s):section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv)each place where transactions have been conducted -------------------------------------------------------------------------- a) Description of the Financial Physiomics plc Ordinary Shares instrument, type of instrument -------------------------------- ---------------------------------------- Identification code ISIN: GB00BDR6W943 -------------------------------- ---------------------------------------- b) Nature of the Transaction Transfer of securities held in paper share certificates to nominee account Interactive Investor Services Nominees Limited. -------------------------------- ---------------------------------------- c) Price(s) and volume(s) Dr Jim Millen Price(s) Volume(s) N/A 500,000 ---------- -------------------------------- ---------------------------------------- d) Aggregated information * Aggregated volume 500,000 N/A * Price -------------------------------- ---------------------------------------- e) Date of the transaction 22 July 2023 -------------------------------- ---------------------------------------- f) Place of the transaction Off market transaction -------------------------------- ----------------------------------------
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour(TM) technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 100 projects, involving over 50 targets and 75 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHRIMRTMTMTBIJ
(END) Dow Jones Newswires
July 25, 2023 02:00 ET (06:00 GMT)
1 Year Physiomics Chart |
1 Month Physiomics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions